- Home
- ACRS vs ORGO Comparison
ACRS vs ORGO Comparison
Compare ACRS & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | ORGO |
|---|---|---|
| Founded | 2012 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 348.6M |
| IPO Year | 2015 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ACRS | ORGO |
|---|---|---|
| Price | $4.59 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $10.20 | $8.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.01 | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | $1,683,000.00 | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | $26.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $1.34 | $2.04 |
| 52 Week High | $5.15 | $7.08 |
Technical Indicators
Market Signals| Indicator | ACRS | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 53.24 | 52.88 |
| Support Level | $4.15 | $2.21 |
| Resistance Level | $4.89 | $2.66 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 37.50 | 74.50 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.